Journal of Dermatology and Clinical Research

Additional Roles of A-MSH or MC1R Signaling in Melanomagenesis Beyond Melanogenesis

Editorial | Open Access Volume 1 | Issue 1 |

  • 0. Both authors contribute equally
  • 1. Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, China
  • 2. Department of Dermatology, Boston University School of Medicine, USA
+ Show More - Show Less
Corresponding Authors
Fang Liu, Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China, Email: roseliufang@hotmail.com Rutao Cui, Department of Dermatology, Boston University School of Medicine, 609 Albany St, Boston, MA 02478, USA

Skin color is determined by epidermal melanin content, the function of which remains poorly understood. Clinically, there is a lower incidence of melanoma in individuals with high levels of constitutive brown/black pigment and/or acquired pigmentation (i.e. tanning). Conversely, individuals with red hair, blue eyes, and inability to tan are at higher risk for developing melanoma. Therefore, pigmentation represents a two-edged sword, with brown/black pigment (eumelanin) being protective and reddish pigment (pheomelanin) predisposing to melanoma [1,2]. However, the lower incidence of melanoma in albinos compared to individuals with red hair/fair skin underscores the complexity of the role of pigmentation in melanoma development. Together, there is essentially one key question of clinical significance to be addressed: why are red-haired individuals so prone to developing melanoma?

The melanocortin-1-receptor (MC1R) is one of the key genes that regulates hair and skin color. MC1R hypomorphic variants are associated with red hair and fair skin in humans. Previous reports demonstrated that three most common variants of MC1R, R151C, R160W, and D294H have a significant association with high melanoma incidence [3-6]. It is well known that melanoma risk attributable to MC1R may arise through the determination of the tanning response of skin to UV light, which can then either ameliorate or exacerbate the genotoxic effects of sunlight [7-9]. However, the connections between MC1R variants and melanoma incidence also identified in darkly-pigmented Caucasians [8], in which MC1R variants are detected from 15% to 33% among dark-haired individuals and to 42% among dark-eyed individuals [8]. Furthermore, MC1R variants are more frequently detected in melanomas with somatic Braf mutation [10-13], suggesting that MC1R variants may have more specific roles in UV-induced mutagenesis. These findings suggest that MC1R signaling pathway may have an additional role in skin carcinogenesis beyond melanogenesis.

α-MSH/MC1R in DNA repair

p53 activation represents a “UV sensor/effector” for skin pigmentation, with its key mechanistic role being the transcriptional activation of POMC [14].The tumor-suppressor protein, p53, plays a central role in the cellular response to UV-induced DNA damage/repair [15].On the other hand, the Abdel-Malek group has demonstrated that α-MSH can prevent UV-induced DNA damage in melanocytes [16-20]. We further demonstrated a novel pigmentation-independent mechanism that underlies MSH-mediated DNA repair following UVB irradiation. We found that α-MSH binds to MC1R and the complex activates adenylate cyclase activity, which in turn activates XPA binding protein 1 (XAB1) that induces nuclear translocation of XPA, a critical factor in controlling nucleotide excision repair (NER) signaling pathways [21] (Figure 1).

MC1R is a regulator of PTEN after UV exposure

To define the mechanism by which α-MSH/MC1R maintains melanocyte viability, we explored links between α-MSH/MC1R and genes regulated by G protein-coupled receptors (GPCR) using animal models and human subjects because MC1R is a GPCR [22]. We found that PTEN expression in melanocytes was significantly lower among people carrying variant alleles of MC1R compared to baseline pre-treatment levels after UV exposure, suggesting that the MC1R status impacts PTEN expression levels in melanocytes after ultraviolet radiation (UVR) exposure [23]. The PTEN/phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway is crucial to many aspects of cell growth and survival [24]. In this signaling pathway, the product of PI3K, phosphatidylinositol,3,4,5 triphosphate or PIP3, recruits AKT to the plasma membrane via directly interacting with the PH-domain of AKT, where AKT becomes fully activated by other kinases including PDK1 and mTORC2, and in turn exerts its crucial roles by inducing cell proliferation and DNA repair [25]. In melanoma, deletion of the PTEN gene is observed in 30-50% of melanoma cell lines and in 5-20% of primary human melanomas [26]. A recent report showed that abrogation of BRafV600E-induced senescence by PI3K pathway activation (e.g. PTEN deletion) contributes to melanoma development [27]. Recent studies have also shown that UVR causes gene alterations of PTEN in skin cells [28].

To characterize the underlying molecular mechanisms, we tested whether MC1R physically interacts with PTEN. We found that MC1R protein interacts with the PTEN-C2 domain, which protects PTEN from degradation, leading to inhibition of AKT phosphorylation after UV exposure [23].

Given the correlation between melanocyte senescence prevalent in melanocytic nevus and individuals with MC1R variants [29], we next detect senescent melanocytes in shMC1R human primary melanocytes following low-dose UVB exposure (25 J/m2 ). We found that MC1R silencing induced melanocyte senescence [23].

The premature senescent phenotype is observed in nevi under pathological conditions such as BRafV600E expression [30]. This is considered as a natural barrier to prevent oncogeneinduced transformation and in most cases, additional inactivation of the p53/p21 and p16/Rb tumor suppressor pathways is required to bypass this senescent phenotype. To identify the critical role of MC1R in melanoma development, we used genetically engineered human immortal melanocytes (hTERT/ p53DD/CDK4(R24C) [31]. We found that depletion of MC1R is not sufficient to confer cellular transformation in genetically engineered human melanocytes [23]. These results indicate that additional genetic alterations are required for transformation of human melanocytes. To this end, it has been reported by multiple groups that oncogenic BRafV600E mutation is detected in over 60% of human melanomas and is considered a driving force to facilitate melanoma development. Thus, we intend to further investigate the role of BRafV600E in MC1R deficiencyinduced melanoma. We found that genetically engineered human melanocytes with simultaneous depletion of MC1R and ectopic expression of BRafV600E resulted in a robust melanocyte mediaindependent growth in vitro [23].

Finally, correlations between MC1R genetic status and PTEN activity in melanomas were characterized. We found that PTEN mutations are significantly (p < 0.05) more frequently detected in melanomas for individuals with wild-type MC1R than those with MC1R variant alleles [23].

A recent report demonstrated that the MC1R-controled pheomelanin pigment pathway produces ultraviolet-radiationindependent carcinogenic that contributes to melanoma development by a mechanism of oxidative damage [32]. Our studies establish the MC1R-PTEN interaction as a central regulator in response of melanocytes to UV exposure. These two studies are complementary each other for further elucidation of the pigmentary and non-pigmentary mechanisms governing melanoma development. These results will broaden our understanding of melanoma development and help us to devise more effective preventive and therapeutic strategies for this deadly malignancy.


1. Takeuchi S, Zhang W, Wakamatsu K, Ito S, Hearing VJ, Kraemer KH, et al. Melanin acts as a potent UVB photosensitizer to cause an atypical mode of cell death in murine skin. Proc Natl Acad Sci U S A. 2004; 101: 15076-15081.

2. Chedekel MR, Smith SK, Post PW, Pokora A, Vessell DL. Photodestruction of pheomelanin: role of oxygen. Proc Natl Acad Sci U S A. 1978; 75: 5395-5399.

3. Palmer JS, Duffy DL, Box NF, Aitken JF, O’Gorman LE, Green AC, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet. 2000; 66: 176-186.

4. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, et al. MC1R variants, melanoma and red hair color phenotype: a metaanalysis. Int J Cancer. 2008; 122: 2753-2760.

5. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanomaprone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2208-2212.

6. Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2005; 97: 998-1007.

7. Kricker A, Armstrong BK, Goumas C, Kanetsky P, Gallagher RP, Begg CB, et al. MC1R genotype may modify the effect of sun exposure on melanoma risk in the GEM study. Cancer Causes Control. 2010; 21: 2137-2147.

8. Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, et al. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer. 2010; 116: 2416-2428.

9. Thomas NE, Kanetsky PA, Edmiston SN, Alexander A, Begg CB, Groben PA, et al. Relationship between germline MC1R variants and BRAFmutant melanoma in a North Carolina population-based study. J Invest Dermatol. 2010; 130: 1463-1465.

10.Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science. 2006; 313: 521-522.

11.Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, Munroe DJ, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol. 2008; 128: 2485-2490.

12.Kim RD, Curtin JA, Bastian BC. Lack of somatic alterations of MC1R in primary melanoma. Pigment Cell Melanoma Res. 2008; 21: 579-582.

13.Scherer D, Rachakonda PS, Angelini S, Mehnert F, Sucker A, Egberts F, et al. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. J Invest Dermatol. 2010; 130: 2844-2848.

14.Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007; 128: 853-864.

15.Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wildtype p53 activates transcription in vitro. Nature. 1992; 358: 83-86.

16.Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes- -a shift in paradigm. Photochem Photobiol. 2008; 84: 501-508.

17.Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R, Kadekaro AL, Swope V, Haskell-Luevano C, et al. alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Melanoma Res. 2009; 22: 635-644.

18.Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, Todorovic A, Koikov LN, McNulty JC, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J. 2006; 20: 1561-1563.

19.Kadekaro AL, Kavanagh R, Kanto H, Terzieva S, Hauser J, Kobayashi N, et al. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res. 2005; 65: 4292-4299.

20.Böhm M, Wolff I, Scholzen TE, Robinson SJ, Healy E, Luger TA, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2005; 280: 5795-5802.

21.Dong L, Wen J, Pier E, Zhang X, Zhang B, Dong F, et al. Melanocytestimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism. Cancer Res. 2010; 70: 3547-3556.

22.García-Borrón JC, Sánchez-Laorden BL, Jiménez-Cervantes C. Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res. 2005; 18: 393-410.

23.Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, et al. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013; 51: 409-422.

24.Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/ AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4: 988-1004.

25.Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129: 1261-1274.

26.Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003; 22: 3113-3122.

27.Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012; 26: 1055-1069.

28.Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat. 2007; 28: 578-588.

29.Ha L, Merlino G, Sviderskaya EV. Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle. 2008; 7: 1944-1948.

30.Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436: 720-724.

31.Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005; 436: 117-122.

32.Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, et al. An ultravioletradiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012; 491: 449-453.


Received : 20 Oct 2013
Accepted : 22 Oct 2013
Published : 24 Oct 2013
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X